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Abstract
This research intends to address the issue of non-alcoholic fatty liver disease. This
disease is an accumulation of fat in the liver that can result in inflammation of the liver, cirrhosis,
steatohepatitis (NASH) and potentially even liver failure. This disease is affecting more and
more people, and the number keeps growing due to the increasing amount of obese Americans.
One reported method to mitigate alcoholic and non-alcoholic liver fibrosis is the modulation of
cannabinoid receptors (CB1 and CB2). While CB1 receptors can facilitate liver fibrosis, the
antagonists can be anti-fibrotic. Not only are the CB1 antagonists anti-fibrotic, but the CB2
receptor agonists are also anti-fibrotic. Because of this property, it is hypothesized that
compounds that obtain both CB1 antagonist activity and CB2 agonist activity would be highly
effective in attenuating liver fibrosis. However, because CB1 antagonists have established
adverse effects on the central nervous system – the brain and spinal cord – these compounds
should not be able to penetrate the CNS. This research focuses on tethering a peripherally
selective CB1 antagonist with one of four different compounds with known CB2 agonist activity.
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One of these four different compounds, when tethered, may help the compound to affect both
CB1 and CB2 receptors, thus making the compound more effective. The compound
AZ11713908 has been noted as a peripherally selective CB1/CB2 agonist, while the other three
compounds are CB2 agonists selective against CB1. Once synthesized, these compounds will be
tested to determine their effect on both the cannabinoid receptors and on liver fibrosis. This
research should serve as the basis of cannabinoid receptor modulator development and potential
NASH treatment and potentially develop interest in the liver fibrosis field.
Christian worldview integration
Our research is informed by a Christian worldview in several important ways. First, our
research is driven by a desire to serve those living with obesity and liver failure. We want to do
this, specifically, by increasing the body of scientific and experimental knowledge about key
receptors in the liver. We are motivated to explore ways to improve liver function because we
believe that every person is created in the image of God. The Christian worldview affirms, and
we embrace, that every human life is valuable and deserves our care and protection.
Additionally, our research may help those working in the pharmaceutical industry to create more
effective and reasonably priced drugs. These drugs in turn can help improve the quality of life of
those who live with common illnesses including obesity and fatty liver disease.
Another way that a Christian worldview influences our research is that it enhances our
appreciation of the body’s systems. According to the theory of evolution, many of the organs
and functions of the body may be remnants from our ancestral past, vestigial from the apes that
preceded us. However, the Christian worldview affirms that our bodies are wonderfully
designed by God and that the organs, systems, and pathways are specifically designed to the
human race. This means that many aspects of the human body can be understood and even
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influenced in ways that benefit our health. Thus the Christian worldview inherently promotes
scientific research, like that which we are performing, in its teachings about the value of human
life and the creative work of God.

